Addictology Expert Patients' Fields of Intervention
HAPEX
Identification and Validation of Addictology Expert Patients' Fields of Intervention With Inpatients for Addictive Disorders
1 other identifier
interventional
69
1 country
1
Brief Summary
Although there are many publications concerning the benefit of the interventions of the self-help movements and peer health mediators in psychiatry, no studies have described the intervention specific to patients with expertise in addictology (EP), nor evaluated their effectiveness. The objective of this study is twofold: identify and define the fields of intervention of EPs adapted to the specific needs of addictology patients. And validate, through a pilot study, the intermediate effectiveness of EP intervention. This EP intervention will be built on the areas of expertise defined in the first step. Intermediate effectiveness will be measured by patients' ability to manage their addiction. The first part of the study will consist of a preliminary qualitative patient-centered study to clarify patients' needs and expectations regarding the content of the EPs' intervention into a one addictology service of the university hospital of Bichat, Paris, France. This will make it possible to translate these needs into fields of expertise to address during the EPs' intervention and will result in the creation of a hetero-questionnaire. The second part of the study will consist of a before-and-after comparative study on inpatients who are their own controls based on the hetero-questionnaire constructed through the qualitative study. This study will identify the main EP's intervention fields in addictology in which EP are more relevant to patients. Thus, their inpatient interventions can be validated and improved, and better carried by addiction professionals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 27, 2020
CompletedStudy Start
First participant enrolled
June 19, 2020
CompletedFirst Posted
Study publicly available on registry
July 7, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 19, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 19, 2021
CompletedOctober 18, 2021
October 1, 2020
11 months
January 27, 2020
October 15, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
median of the difference of the score of the competency questionnaires between D0 and H48 will be compared between the group before and the group after
This EP intervention will be built on the areas of expertise defined in the first step. Intermediate effectiveness will be measured by patients' ability to manage their addiction. This will be measured by a hetero-questionnaire, created by the first part of the study, evaluating the skills acquired by patients before and after this intervention. As this is a new scale created thanks to the forst part of the study, the investigators don't know what will be the minimum, the maximum or/and the relation between the score and the outcome
48 hours
Study Arms (1)
Expert patient in addictology
EXPERIMENTALbefore/ after comparison, each patients being its own control
Interventions
EP's Intervention, with patients hospitalized for addiction withdrawal. These are weekly individual interviews, in room, proposed by the EPs to inpatients. The content of the intervention will be defined trough the results of step one of the study.
Eligibility Criteria
You may qualify if:
- Patients hospitalized in the addictology department at the Bichat-Claude Bernard Hospital in Paris, for withdrawal.
- Substance use disorder, diagnosed according to the criteria of the DSM-5, i.e. at least 2 diagnostic criteria.
- Patients who have received information about the research and signed the consent form.
You may not qualify if:
- Severe cognitive impairment i.e. MoCA scale \< or = 10
- Severe psychiatric conditions assessed using the MINI scale : Acute psychotic episode, Manic or hypomaniacal episode, Severe depression
- non comprehension of french
- patient Under guardianship or curatorship
- patient refusal
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Département psychiatrie et addictologie Bichat Claude Bernard
Paris, 75018, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chanaëlle OBADIA, MD
APHP
- STUDY DIRECTOR
Aurélie BOURMAUD, PhD
APHP
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 27, 2020
First Posted
July 7, 2020
Study Start
June 19, 2020
Primary Completion
May 19, 2021
Study Completion
May 19, 2021
Last Updated
October 18, 2021
Record last verified: 2020-10
Data Sharing
- IPD Sharing
- Will not share